Juan Manuel Sepúlveda-Sánchez
YOU?
Author Swipe
View article: IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial Open
TGR shows emerging utility as a quantitative measure for assessing treatment efficacy in glioma. We evaluated three distinct TGR models using volumetric data from patients with mIDH1/2 diffuse glioma from the Phase 3 INDIGO trial (NCT04164…
View article: CTNI-74. PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES
CTNI-74. PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES Open
Berubicin is a unique anthracycline engineered to have the ability to cross the blood-brain barrier (BBB). Herein we present the primary results from a large global trial of Berubicin vs. Lomustine randomizing patients with progressive dis…
View article: JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB
JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB Open
BACKGROUND Grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas are slowly progressive, malignant, incurable brain tumors with poor long-term prognosis. Patients may experience tumor-related symptoms (eg seizures) that impact t…
View article: OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209
OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209 Open
BACKGROUND FGFR genomic alterations occur in approximately 8% of gliomas. Inhibition of FGFR1-3 with pemigatinib showed antitumor activity in a multihistology basket trial (FIGHT-207) in which approximately 10% of participants (pts) had re…
View article: P12.25.B A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.
P12.25.B A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT. Open
BACKGROUND Glioblastoma (GBM) is a universally deadly disease with dismal prognosis. The O6-methylguanine methyltransferase (MGMT) promoter methylation is both predictive in response to standard chemoradiation, as well as prognosis, and un…
View article: OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL
OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL Open
BACKGROUND In the Phase 3 INDIGO trial (NCT04164901), vorasidenib, an oral, brain-penetrant, dual inhibitor of mutated isocitrate dehydrogenase 1/2 (mIDH1/2), improved progression-free survival (PFS) versus placebo in patients with mIDH1/2…
View article: OR34-04 Human Pancreatic Islet Immuno-Metabolism Response after Cytokine Administration
OR34-04 Human Pancreatic Islet Immuno-Metabolism Response after Cytokine Administration Open
Disclosure: M. D'silva: None. B. Malachowska: None. Y. Qiu: None. J. Sepulveda: None. R. Chang: None. S. Sidoli: None. J.L. Nadler: None. I.J. Kurland: Scorpion Therapeutics. An important early hallmark of Type I Diabetes Mellitus (T1D) is…
View article: Correction to: Efficacy and safety of endoscopic compared with open surgical repair of cerebrospinal fluid fistulas: a systematic review and meta-analysis
Correction to: Efficacy and safety of endoscopic compared with open surgical repair of cerebrospinal fluid fistulas: a systematic review and meta-analysis Open
View article: Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study Open
Treatment options for patients with gliomas remain limited, and prognosis is generally poor. While next-generation sequencing (NGS) is increasingly used to stratify glioma patients and guide therapy, its implementation in routine clinical …
View article: PERCEPTION OF THE IMPACT OF THE MENSTRUAL CYCLE ON THE CREATIVITY OF MEDICAL STUDENTS AT A MEXICAN UNIVERSITY
PERCEPTION OF THE IMPACT OF THE MENSTRUAL CYCLE ON THE CREATIVITY OF MEDICAL STUDENTS AT A MEXICAN UNIVERSITY Open
The present research aimed to map and identify the perception of creativity among undergraduate students at a Mexican university, explicitly focusing on Medicine. The objective was to comprehensively analyze how these perceptions could var…
View article: Prognostic value of 1D, 2D and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: radiological <i>post-hoc</i> analysis of the EORTC-BTG-1320 trial
Prognostic value of 1D, 2D and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: radiological <i>post-hoc</i> analysis of the EORTC-BTG-1320 trial Open
Background Although differential prognostic value of 1D, 2D and volumetric meningioma size assessment has been reported, RANO meningioma criteria rely on bidimensional measurements. Methods In this post-hoc analysis of the EORTC-BTG 1320 t…
View article: Supplementary Figure 5 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Figure 5 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary figure S5. DAC generated a significantly increased increase in antigen presentation and leukocyte recruitment gene signatures in PDTF assays.
View article: Supplementary Table S1 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Table S1 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary Table S1
View article: Supplementary Table S2 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Table S2 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary Table S2
View article: Supplementary Table S6 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Table S6 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary Table S6
View article: Supplementary Table S5 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Table S5 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary Table S5
View article: Supplementary Figure 3 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Figure 3 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary figure S3. Characterization of TRIB2 expression in murine glioma models.
View article: Supplementary Figure 2 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Figure 2 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary figure S2. TRIB2 expression is associated with proliferation processes and vascular cells in GBM.
View article: Data from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Data from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
The lack of response of glioblastoma (GBM) to immunotherapy is closely related to the limited number of T cells in the tumor microenvironment. However, it is still not known why GBM is characterized by an immune-cold tumor microenvironment…
View article: Supplementary Table S3 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Table S3 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary Table S3
View article: Supplementary Figure 4 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Figure 4 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary figure S4. Molecular characterization of TRIB2-associated methyltransferases and their role in gene expression and immune regulation.
View article: Supplementary Table S4 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Table S4 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary Table S4
View article: Supplementary Figure 1 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary Figure 1 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy Open
Supplementary figure S1. Genes highly expressed in GBM compared to BrM tumors.
View article: Comprehensive immune ageing reveals TREM2/TIM3 myeloid cells drive brain immune evasion
Comprehensive immune ageing reveals TREM2/TIM3 myeloid cells drive brain immune evasion Open
View article: Patient-Derived Surgical samples reveal patterns of glioblastoma infiltration and tumor microenvironment at the tumor margin
Patient-Derived Surgical samples reveal patterns of glioblastoma infiltration and tumor microenvironment at the tumor margin Open
Background Glioblastoma (GBM) is a highly aggressive cancer with near-universal recurrence, often due to residual tumor cells that persist after aggressive standard of care treatment. This study aimed to characterize tumor infiltration and…
View article: S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture
S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture Open
Background: Glioblastoma IDH wild type (GBM IDH wt) has a poor prognosis and a strongly associated with inflammatory processes. Inflammatory molecules generate positive feedback with tumor cells fueling tumor growth as well as recru…
View article: 10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS
10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS Open
INTRODUCTION The Phase 3 INDIGO study (NCT04164901) evaluated vorasidenib, an oral,brain-penetrant, dual inhibitor of mutated isocitrate dehydrogenase 1/2 (mIDH1/2), in patients with mIDH1/2 diffuse glioma. The primary endpoint of progress…
View article: Supplementary Table S2 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Supplementary Table S2 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer Open
All causality TEAEs
View article: Supplementary Legend from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Supplementary Legend from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer Open
Supplementary Legend
View article: Supplementary Figure S2 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Supplementary Figure S2 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer Open
LY3200882 pharmacokinetics parameters